Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System

(2023) Toru Ogura et al.   CLINICAL DRUG INVESTIGATION

Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions

(2023) Zhiyuan Lu et al.   BMC Medical Research Methodology

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system ( FAERS ) database

(2022) Yamin Shu et al.   Cancer Medicine

Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications

(2022) Jingjing Yu et al.   CLINICAL THERAPEUTICS

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations

(2021) Patrick C. Lee et al.   Cancers

Infigratinib: First Approval

(2021) Connie Kang   DRUGS

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

(2021) Anuhya Kommalapati et al.   Cancers

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

(2021) Milind Javle et al.   Lancet Gastroenterology & Hepatology

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, And Management Guidelines

(2020) Mario E. Lacouture et al.   ONCOLOGIST

Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma

(2020) Gehan Botrus et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cholangiocarcinoma: Epidemiology and risk factors

(2019) Shahid A. Khan et al.   LIVER INTERNATIONAL

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

(2018) Ciara M. Kelly et al.   INVESTIGATIONAL NEW DRUGS

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications

(2016) Ruwen Böhm et al.   PLoS One

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

A Review of Statistical Methods for Safety Surveillance

(2013) Lan Huang et al.   Therapeutic Innovation & Regulatory Science